Sifalimumab

Sifalimumab ?
Monoclonal antibody
Type Whole antibody
Source Human
Target Interferon α
Clinical data
Pregnancy cat.  ?
Legal status  ?
Identifiers
CAS number 1143503-67-6 N
ATC code None
UNII XOY1YA7RMC Y
Chemical data
Formula C6518H10008N1724O2032S38 
Mol. mass 146.25 kDa
 N(what is this?)  (verify)

Sifalimumab is a human monoclonal antibody designed for the treatment of SLE, dermatomyositis, and polymyositis.[1]

Sifalimumab was developed by MedImmune.

References

  1. ^ "Statement On A Nonproprietary Name Adopted By The USAN Council: Sifalimumab". American Medical Association. http://www.ama-assn.org/ama1/pub/upload/mm/365/sifalimumab.pdf. 
Immune system ("-l(i[m])-")
Human ("-limu-")

immunosuppression: Adalimumab • Atorolimumab • Brodalumab • Carlumab • Fresolimumab • Golimumab • Lerdelimumab • Mavrilimumab • Metelimumab • Morolimumab • Namilumab • Oxelumab • Sarilumab • Sifalimumab • Tabalumab • Urelumab

immune activation: Ipilimumab • Tremelimumab

other: Bertilimumab • Zanolimumab
Mouse ("-limo-")
Chimeric ("-lixi-")
Humanized ("-lizu-")
Chimeric + humanized
("-lixizu-")
Interleukin ("-k(i[n])-")
Human ("-kinu-")
Humanized ("-kizu-", "-kinzu-")
Inflammatory lesions ("-les-")
Mouse ("-leso-")

M: LMC

cell/phys/auag/auab/comp, igrc

imdf/ipig/hyps/tumr

proc, drug(L3/4)